<- Go Home
Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Market Cap
$21.4B
Volume
713.8K
Cash and Equivalents
$1.1B
EBITDA
$493.4M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$1.7B
Profit Margin
N/A
52 Week High
$329.33
52 Week Low
$173.00
Dividend
N/A
Price / Book Value
N/A
Price / Earnings
91.35
Price / Tangible Book Value
N/A
Enterprise Value
$21.6B
Enterprise Value / EBITDA
45.49
Operating Income
$407.2M
Return on Equity
19.18%
Return on Assets
N/A
Cash and Short Term Investments
$1.1B
Debt
$1.4B
Equity
$1.5B
Revenue
$2.4B
Unlevered FCF
N/A
Sector
Health Care Equipment and Supplies
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium